Merus News

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage...

PR NewswireMay 17 12:50 ET

Merus (MRUS) Initiated With a Buy at Truist Financial

TipRanksMay 14 10:05 ET

Bank of America Securities Remains a Buy on Merus (MRUS)

TipRanksMay 13 09:37 ET

Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation

By Dean Seal Merus said federal regulators have granted breakthrough therapy designation to its carcinoma treatment petosemtamab.

WSJMay 13 08:38 ET

Express News | FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

BenzingaMay 13 08:21 ET

Express News | Merus NV: Plans to Provide Updated Efficacy, Durability and Safety Data From This Cohort in Second Half of 2024

ReutersMay 13 08:04 ET

Express News | Merus NV: Petosemtamab Granted Btd for Treatment of Previously Treated Hnscc Utrecht

ReutersMay 13 08:04 ET

Express News | Petosemtamab Granted Breakthrough Therapy Designation by the U.S. FDA

ReutersMay 13 08:00 ET

Buy Rating on Merus Stock Amid Anticipation of Positive Clinical Trial Results and Growing Investor Interest

TipRanksMay 13 06:56 ET

Express News | Needham Reiterates Buy on Merus, Maintains $66 Price Target

BenzingaMay 13 06:42 ET

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Merus (NASDAQ:MRUS) stock is up 116% in the last year, providing strong gains for shareholders.

Simply Wall StMay 10 08:45 ET

Express News | HC Wainwright & Co. Reiterates Buy on Merus, Maintains $65 Price Target

BenzingaMay 9 07:28 ET

Merus Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 38.03% HC Wainwright & Co. → $65 Reiterates Buy → Buy 04/11/2024 40.16% Needham → $66 Reiterate

BenzingaMay 9 07:27 ET

Buy Rating Affirmed for Merus on Promising HNSCC Clinical Data and Competitive Outlook

TipRanksMay 9 06:36 ET

Express News | Merus NV : Guggenheim Raises Target Price to $57 From $56

ReutersMay 9 06:21 ET

Merus Q1 EPS $(0.59) Beats $(0.81) Estimate, Sales $7.89M Miss $9.74M Estimate

Merus (NASDAQ:MRUS) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.81) by 27.16 percent. This is a 31.4 percent increase over losses of $(0.86) per sha

BenzingaMay 8 18:35 ET

Express News | Merus NV Q1 Shr View $-0.81 -- Lseg Ibes Data

ReutersMay 8 17:13 ET

Express News | Merus NV: Qtrly Shr Loss $0.59

ReutersMay 8 17:13 ET

Express News | Merus NV: Based on Current Operating Plan Co Expected to Fund Merus' Operations Into 2027

ReutersMay 8 17:11 ET

Earnings Flash (MRUS) MERUS N.V. Posts Q1 Revenue $7.9M

04:27 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (MRUS) MERUS N.V. Posts Q1 Revenue $7.9M

MT NewswiresMay 8 16:27 ET